Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Background Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the
management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and multiple …

Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …

Background CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a
promising treatment modality for an increasing number of B-cell malignancies. However …

Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …

Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can
predispose for severe infectious complications. Current grading systems, such as the …

Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary treatment modality used to
treat haematological malignancies. Lymphocytes are engineered to produce CARs directed …